ClinicalTrials.gg
RecruitingNCT05965193Updated Mar 28, 2024

Normobaric Hyperoxia Combined With Intravenous Thrombolysis for Acute Ischemic Stroke:Longterm Outcome (OPENS-3L)

A Phase 3 interventional study of Normobaric Hyperoxia and Nasal oxygen in Acute Ischemic Stroke, sponsored by Ji Xunming,MD,PhD. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-03-28.

Sponsored by Ji Xunming,MD,PhD · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2025, 1 year 2 months ago, but the record still lists the study as recruiting.
  • Started Aug 2023; still recruiting 3 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,230
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 753 studies in Ischemic Stroke with a site in China — 380 open to participants now, 399 under way, 78 of them phase 3. Ischemic Stroke · China.

Planned enrollment
75th of 565
1,230 · median 270
Started
2023
with 91 others
Phase 3
111 of 753
65 open now
Primary completion
2025-08
later than 60 of 398 live
Registered
366th of 753
by date

Among the 753 studies in Ischemic Stroke with a site in China, this one is the 75th largest by planned enrollment of the 565 interventional ones that give a count, is one of 92 that started in 2023, is one of 111 in phase 3, reaches primary completion later than 60 of the 398 other live ones, and was the 366th registered.

Ischemic Stroke

2,625 studies on the registry are indexed under Ischemic Stroke; 982 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

380 of the 753 studies in Ischemic Stroke with a site in China are open now. Recruiting first, the newest first:

375 more — sign in →

All 380 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 402 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 753 studies in Ischemic Stroke with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to determine the long-term efficacy and safety of Normobaric Hyperoxia combined with intravenous thrombolysis for acute ischemic stroke.

Read the detailed description

In this study, cases of acute ischemic stroke who undergo intravenous thrombolysis within 4.5 hours from onset are included. The Normobaric Hyperoxia(NBO) group receive basic intravenous thrombolysis and given 100% oxygen inhalation at a ventilation rate of 10L/ min using a sealed non-ventilating oxygen storage mask and keep giving oxygen for 4 hours. The control group receive basic intravenous thrombolysis and given oxygen inhalation at a ventilation rate of 1L/min using nasal cannula and keep giving oxygen for 4 hours. The investigators aimed to determine the long-term effect of Normobaric Hyperoxia combined with intravenous thrombolysis for acute ischemic stroke.

03

Conditions studied

  • Acute Ischemic Stroke

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age≥18 years;
  2. The time from onset to randomization is within 4.5 hours of onset;
  3. The clinical diagnosis is acute ischemic stroke (the criteria followed the Chinese Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke 2018);
  4. Baseline NIHSS (at the time of randomization) should be ≥5 and ≤25 points;
  5. Pre-stroke mRS score≤1 points;
  6. from the patient or surrogate.

Exclusion criteria

Exclusion Criteria:

  1. Intracranial hemorrhage (including parenchymal hemorrhage, intraventricular hemorrhage, subarachnoid hemorrhage, subdural/extradural hematoma, etc.);
  2. Past history of intracranial hemorrhage;
  3. Rapid neurological function improvement, NIHSS score less than 5 points;
  4. Presence of proximal arterial occlusion on computed tomography angiography(CTA)/magnetic resonance angiography(MRA) (e.g., intracranial internal carotid artery(ICA), middle cerebral arterial(MCA)-M1, and vertebrobasilar arteries);
  5. Massive anterior cerebral infarction identified by CT or MRI (ASPECT \< 6 or lesions larger than one third of the territory of the middle cerebral artery);
  6. Intended to proceed endovascular treatment;
  7. Pregnant women, or planning to become pregnant during the trial;
  8. A history of severe head trauma or stroke within 3 months;
  9. A history of intracranial or spinal surgery within 3 months;
  10. A history of gastrointestinal or urinary bleeding within 3 weeks;
  11. two weeks of major surgery;
  12. Arterial puncture was performed at the hemostasis site that was not easily compressed within 1 week;
  13. Active visceral bleeding;
  14. Intracranial tumors, large intracranial aneurysms;
  15. Aortic arch dissection was found;
  16. Severe, sustained hypertension (Systolic Blood Pressure >185 mmHg or Diastolic Blood Pressure >110 mmHg);
  17. Baseline blood glucose of \<50mg/dL (2.78 mmol) or >400mg/dL (22.20 mmol);
  18. Oral warfarin anticoagulant with (INR)>1.7 or PT>15 s;
  19. Heparin treatment was received within 24 h;
  20. Thrombin inhibitors or factor Xa inhibitors were used within 48 h;
  21. Propensity for acute bleeding, including counts of less than 100×109/ L or otherwise;
  22. Hereditary or acquired bleeding constitution;
  23. Onset with seizures;
  24. Severe liver and kidney dysfunction;
  25. Active and or acute respiratory distress syndrome;
  26. Patients with anemia or polycythemia vera or other situations that require urgent oxygen inhalation;
  27. Patients with upper gastrointestinal bleeding or nausea or vomiting so that they cannot cooperate with the mask to inhale oxygen;
  28. \< 1 year;
  29. Patients who could not complete the 90-day follow-up;
  30. Participation in other clinical trials within 3 months prior to screening;
  31. Unsuitability or participation in this study as judged by the Investigator may result in subjects being exposed to greater risk.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
1,230 participants (estimated)

Study arms

  • Experimental
    NBO group

    Normobaric Hyperoxia combined with intravenous thrombolysis

    Device: Normobaric Hyperoxia · Drug: Intravenous thrombolysis(rt-PA)

  • Placebo comparator
    Control group

    Nasal oxygen combined with intravenous thrombolysis

    Device: Nasal oxygen · Drug: Intravenous thrombolysis(rt-PA)

Interventions

  • DeviceNormobaric Hyperoxia

    Within 4.5 hours after stroke onset, patients were randomized into the NBO group and immediately given 100% oxygen inhalation (no more than 30 minutes after randomization) at a ventilation rate of 10L/ min using a sealed non-ventilating oxygen storage mask and keep giving oxygen for 4 hours. If the patient needs to be intubated with a ventilator to maintain ventilation, the FiO2 should be set to 1.0.

  • DeviceNasal oxygen

    For nasal oxygen group, Patients were immediately given oxygen inhalation (no more than 30 minutes after randomization) at a ventilation rate of 1L/min using nasal cannula and keep giving oxygen for 4 hours. If the patient needs to be intubated with a ventilator to maintain, the FiO2 should be set to 0.3 and gradualy incerased if spO2≤94%.

  • DrugTissue Plasminogen ActivatorStudies of Tissue Plasminogen ActivatorTissue Plasminogen Activator pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    10% dose of rt-PA (0.9 mg/kg) is given as bolus and the rest given as an infusion over the remaining 1 hour. Maximum dose 90mg.

06

What researchers measure

Primary outcomes

  1. Utility-weighted modified Rankin scale scores

    Utility-weighted modified Rankin scale scores

    Time frame: 12 months±14 days after randomization

Secondary outcomes

  1. Cerebral infarct volume

    The infarct volume of cerebral infarct is evaluated by MRI

    Time frame: 24-48hours after randomization

  2. modified Rankin Scale (mRS) score

    Ordinal distribution of mRS at 12 months±14 days after randomization; mRS score ranges from 0 to 5, and the higher score means a worse outcome

    Time frame: 12 months±14 days after randomization

  3. Good functional outcome

    Proportion of subjects with modified rankin scale (mRS) 0-2 at 12 months±14 days after randomization

    Time frame: 12 months±14 days after randomization

  4. Excellent functional outcome

    Proportion of subjects with modified Rankin Scale (mRS) 0-1 at 6 months±14 days after randomization; mRS score ranges from 0 to 5, and the higher score means a worse outcome

    Time frame: 6 months±14 days after randomization

  5. Good functional outcome

    Proportion of subjects with modified rankin scale (mRS) 0-2 at 6 months±14 days after randomization

    Time frame: 6 months±14 days after randomization

  6. modified Rankin Scale (mRS) score

    Ordinal distribution of mRS at 6 months±14 days after randomization; mRS score ranges from 0 to 5, and the higher score means a worse outcome

    Time frame: 6 months±14 days after randomization

  7. Scores assessed by National Institutes of Health Stroke Scale(NIHSS)

    Scores on the National Institutes of Health Stroke Scale (NIHSS) range from 0 to 42, with higher scores indicating more severe neurologic deficits

    Time frame: 4 ± 2 hours, 24 ± 6 hours, 72 ± 24 hours, 7 ± 2 days after randomization

  8. Barthel Index (BI)

    The BI is an ordinal disability score of 10 categories (range from 0 to 100, higher values indicate better prognosis)

    Time frame: 6 months±14 days,12 months±14 days after randomization

  9. EuroQol five dimensions questionnaire(EQ-5D)

    The score ranges from 0 to 100, with higher scores indicating optimal health

    Time frame: 6 months±14 days,12 months±14 days after randomization

  10. Stroke-related mortality

    Safety endpoint; the proportion of stroke related deaths in each group

    Time frame: 12 months±14 days after randomization

  11. All-cause mortality

    Safety endpoint; the proportion of all patients who died in each group

    Time frame: 12 months±14 days after randomization

  12. Symptomatic intracranial hemorrhage

    Proportion of subjects with symptomatic intracranial hemorrhage at 24 ± 6 hours after randomization (defined by ECASSII and ECASS III)

    Time frame: 24 ± 6 hours after randomization

  13. Asymptomatic intracranial hemorrhage

    The incidence of asymptomatic intracranial hemorrhage at 24 ± 6 hours after randomization

    Time frame: 24 ± 6 hours after randomization

  14. PH2 intracranial hemorrhage

    The incidence of PH2 intracranial hemorrhage at 24 ± 6 hours after randomization (according to SITS standards)

    Time frame: 24 ± 6 hours after randomization

  15. Adverse events/serious adverse events

    Safety endpoint; the proportion of adverse events/serious adverse events in each group

    Time frame: 24 ± 12 hours, 7 ± 2 days, 90± 7 days, 6 months±14 days,12 months±14 days after randomization

  16. Excellent functional outcome

    Proportion of subjects with modified Rankin Scale (mRS) 0-1 at 12 months±14 days after randomization; mRS score ranges from 0 to 5, and the higher score means a worse outcome

    Time frame: 12 months±14 days after randomization

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2023 (actual). Primary completion is estimated for Aug 2025, 24 months after the start.

Of 145 non-industry phase 3 interventional studies under Ischemic Stroke, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 62. This study's planned 24 months is below that.

Counting every sponsor, half of 167 studies reached it within 30 months; a quarter within 19 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 14, 2023
First posted
Jul 28, 2023
StartActual
Aug 17, 2023
Primary completionEst.
Aug 30, 2025
CompletionEst.
Oct 30, 2025
Last update
Mar 28, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 28, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05965193
Lead sponsor
Ji Xunming,MD,PhD
Collaborators
Beijing Friendship Hospital, Beijing Shijitan Hospital, Capital Medical University, Beijing Tongren Hospital, People's Hospital of Beijing Daxing District, Tianjin Huanhu Hospital, Guizhou Provincial People's Hospital, Shandong Provincial Hospital, The First Affiliated Hospital of Soochow University, The First Affiliated Hospital of Zhengzhou University, The Affiliated Hospital of Xuzhou Medical University, Jining First People's Hospital, Linyi People's Hospital, Nanyang Central Hospital, Rizhao People's Hospital, Zhumadian Central Hospital, Second Affiliated Hospital of Nanchang University, Affiliated Hospital of Nantong University, The Second Hospital of Anhui Medical University, Changsha Central Hospital
Responsible party
Ji Xunming,MD,PhD (Professor, Capital Medical University) — Sponsor-investigator
First posted
Jul 28, 2023
Start date
Aug 17, 2023
Primary completion
Aug 30, 2025 (estimated)
Completion
Oct 30, 2025 (estimated)
Last update
Mar 28, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion